Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12,814 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors.
Kilian M, Sheinin R, Tan CL, Friedrich M, Krämer C, Kaminitz A, Sanghvi K, Lindner K, Chih YC, Cichon F, Richter B, Jung S, Jähne K, Ratliff M, Prins RM, Etminan N, von Deimling A, Wick W, Madi A, Bunse L, Platten M. Kilian M, et al. Among authors: jung s. Cancer Cell. 2023 Feb 13;41(2):235-251.e9. doi: 10.1016/j.ccell.2022.12.007. Epub 2023 Jan 12. Cancer Cell. 2023. PMID: 36638785 Free article.
T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas.
Kilian M, Friedrich M, Sanghvi K, Green E, Pusch S, Kawauchi D, Löwer M, Sonner JK, Krämer C, Zaman J, Jung S, Breckwoldt MO, Willimsky G, Eichmüller SB, von Deimling A, Wick W, Sahm F, Platten M, Bunse L. Kilian M, et al. Among authors: jung s. Clin Cancer Res. 2022 Jan 15;28(2):378-389. doi: 10.1158/1078-0432.CCR-21-1881. Epub 2021 Nov 15. Clin Cancer Res. 2022. PMID: 34782365 Free PMC article.
T cell receptor dynamic and transcriptional determinants of T cell expansion in glioma-infiltrating T cells.
Lu KH, Michel J, Kilian M, Aslan K, Qi H, Kehl N, Jung S, Sanghvi K, Lindner K, Zhang XW, Green EW, Poschke I, Ratliff M, Bunse T, Sahm F, von Deimling A, Wick W, Platten M, Bunse L. Lu KH, et al. Among authors: jung s. Neurooncol Adv. 2022 Aug 31;4(1):vdac140. doi: 10.1093/noajnl/vdac140. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 36196364 Free PMC article.
The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillance.
Kilian M, Friedrich MJ, Lu KH, Vonhören D, Jansky S, Michel J, Keib A, Stange S, Hackert N, Kehl N, Hahn M, Habel A, Jung S, Jähne K, Sahm F, Betge J, Cerwenka A, Westermann F, Dreger P, Raab MS, Meindl-Beinker NM, Ebert M, Bunse L, Müller-Tidow C, Schmitt M, Platten M. Kilian M, et al. Among authors: jung s. Sci Immunol. 2024 May 3;9(95):eadj7970. doi: 10.1126/sciimmunol.adj7970. Epub 2024 May 3. Sci Immunol. 2024. PMID: 38701193
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
Li R, Shah PH, Stewart TF, Nam JK, Bivalacqua TJ, Lamm DL, Uchio EM, Geynisman DM, Jacob JM, Meeks JJ, Dickstein R, Pearce SM, Kang SH, Jung SI, Kamat AM, Burke JM, Keegan KA, Steinberg GD. Li R, et al. Among authors: jung si. Nat Med. 2024 Jun 6. doi: 10.1038/s41591-024-03025-3. Online ahead of print. Nat Med. 2024. PMID: 38844794
Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KMMWP2201 study.
Lee JH, Choi J, Min CK, Park SS, Jo JC, Lee YJ, Kim JS, Eom HS, Jung J, Moon JH, Cho HJ, Lee MW, Yoon SS, Byun JM, Lee JH, Lee JJ, Jung SH, Shin HJ, Kim DY, Yi JH, Lee SS, Do YR, Yoon DH, Cho H, Lee WS, Lee HS, Uhm J, Kim HJ, Jang HR, Kim SH, Kim K. Lee JH, et al. Among authors: jung sh. Haematologica. 2024 Jun 6. doi: 10.3324/haematol.2024.285534. Online ahead of print. Haematologica. 2024. PMID: 38841794
12,814 results
You have reached the last available page of results. Please see the User Guide for more information.